Molecular etiology of a dominant form of type III hyperlipoproteinemia caused by R142C substitution in apoE4

Journal of Lipid Research

Volumn 52, Issue 1, 2011, Pages 45-56

  Vezeridis, Alexander M ^a   Drosatos, Konstantinos ^a,b   Zannis, Vassilis I ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Columbia University School of Medicine ^*  (United States)

Author keywords

Apolipoprotein E; Gene transfer; Hypertriglyceridemia; Lecithin: Cholesterol acyl transferase; Lipoprotein lipase; Recombinant adenovirus

Indexed keywords

APOLIPOPROTEIN E4; ARGININE; CYSTEINE; HIGH DENSITY LIPOPROTEIN; INTERMEDIATE DENSITY LIPOPROTEIN; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL ESTERIFICATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; FEMALE; HYPERLIPOPROTEINEMIA TYPE 3; HYPERTRIGLYCERIDEMIA; LIPID HYDROLYSIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; APOLIPOPROTEIN E4; CELLS, CULTURED; HUMANS; HYPERLIPOPROTEINEMIA TYPE III; MICE; MICE, TRANSGENIC; MICROSCOPY, ELECTRON; MUTATION; PHENOTYPE; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; TRIGLYCERIDES;

EID: 78650883996     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M008409     Document Type: Article

References (51)

1. Plump , A. S. , J. D. Smith , T. Hayek , K. Aalto-Setala , A. Walsh , J. G. Verstuyft , E. M. Rubin, and J. L. Breslow. 1992 . Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-defi cient mice created by homologous recombination in ES cells. Cell . 71 : 343-353.
2. Schaefer , E. J. , R. E. Gregg , G. Ghiselli , T. M. Forte , J. M. Ordovas , L. A. Zech , and H. B. Brewer, Jr. 1986 . Familial apolipoprotein E deficiency. J. Clin. Invest. 78 : 1206-1219.
3. Reddick , R. L. , S. H. Zhang , and N. Maeda . 1994 . Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression. Arterioscler. Thromb. 14 : 141-147.
4. Herz , J. , and T. E. Willnow . 1995 . Lipoprotein and receptor interactions in vivo. Curr. Opin. Lipidol. 6 : 97-103.
5. Kim , D. H. , H. Iijima , K. Goto , J. Sakai , H. Ishii , H. J. Kim , H. Suzuki, H. Kondo, S. Saeki, and T. Yamamoto. 1996 . Human apolipoprotein E receptor 2. A novel lipoprotein receptor of the low density lipoprotein receptor family predominantly expressed in brain. J. Biol. Chem. 271 : 8373-8380.
6. Takahashi , S. , Y. Kawarabayasi , T. Nakai , J. Sakai , and T. Yamamoto . 1992 . Rabbit very low density lipoprotein receptor: a low density lipoprotein receptor-like protein with distinct ligand specifi city. Proc. Natl. Acad. Sci. USA . 89 : 9252-9256.
7. Mahley , R. W. , and S. C. Rall , Jr . 2001 . Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In C. R. Scriver, A. L. Beaudet, D. Valle, et al., editors. The Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill, NY. 2835-2862.
8. Rall , S. C. , Jr ., and R. W. Mahley . 1992 . The role of apolipoprotein E genetic variants in lipoprotein disorders. J. Intern. Med. 231 : 653-659.
9. Kypreos , K. E. , and V. I. Zannis . 2007 . Pathway of biogenesis of apolipoprotein E-containing HDL in vivo with the participation of ABCA1 and LCAT. Biochem. J. 403 : 359-367.
10. Breslow , J. L. , V. I. Zannis , T. R. SanGiacomo , J. L. Third , T. Tracy , and C. J. Glueck . 1982 . Studies of familial type III hyperlipoproteinemia using as a genetic marker the apoE phenotype E2/2. J. Lipid Res. 23 : 1224-1235.
11. Havel , R. J. , and J. P. Kane . 1973 . Primary dysbetalipoproteinemia: predominance of a specifi c apoprotein species in triglyceride-rich lipoproteins. Proc. Natl. Acad. Sci. USA . 70 : 2015-2019.
12. Zannis , V. I. , D. Kardassis , and E. E. Zanni . 1993 . Genetic mutations affecting human lipoproteins, their receptors, and their enzymes. Adv. Hum. Genet. 21 : 145-319.
13. Horie , Y. , S. Fazio , J. R. Westerlund , K. H. Weisgraber , and S. C. Rall , Jr . 1992 . The functional characteristics of a human apolipoprotein E variant (cysteine at residue 142) may explain its association with dominant expression of type III hyperlipoproteinemia. J. Biol. Chem. 267 : 1962-1968.
14. Chroni , A. , T. Liu , I. Gorshkova , H. Y. Kan , Y. Uehara , A. Von Eckardstein , and V. I. Zannis. 2003 . The central helices of apoA-I can promote ATP-binding cassette transporter A1 (ABCA1)-mediated lipid effl ux. Amino acid residues 220-231 of the wild-type apoA-I are required for lipid effl ux in vitro and high density lipoprotein formation in vivo. J. Biol. Chem. 278 : 6719-6730.
15. Liu , T. , M. Krieger , H. Y. Kan , and V. I. Zannis . 2002 . The effects of mutations in helices 4 and 6 of apoA-I on scavenger receptor class B type I (SR-BI)-mediated cholesterol effl ux suggest that formation of a productive complex between reconstituted high density lipoprotein and SR-BI is required for effi cient lipid transport. J. Biol. Chem. 277 : 21576-21584.
16. Kypreos , K. E. , K. W. Van Dijk , Z. A. van Der , L. M. Havekes , and V. I. Zannis . 2001 . Domains of apolipoprotein E contributing to triglyceride and cholesterol homeostasis in vivo. Carboxyl-terminal region 203-299 promotes hepatic very low density lipoproteintriglyceride secretion. J. Biol. Chem. 276 : 19778-19786.
17. He , T. C. , S. Zhou , L. T. da Costa , J. Yu , K. W. Kinzler , and B. Vogelstein . 1998 . A simplifi ed system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. USA . 95 : 2509-2514.
18. Chroni , A. , H. Y. Kan , A. Shkodrani , T. Liu , and V. I. Zannis . 2005 . Deletions of helices 2 and 3 of human apoA-I are associated with severe dyslipidemia following adenovirus-mediated gene transfer in apoA-I-defi cient mice. Biochemistry . 44 : 4108-4117.
19. Chroni , A. , A. Duka , H. Y. Kan , T. Liu , and V. I. Zannis . 2005 . Point mutations in apolipoprotein a-I mimic the phenotype observed in patients with classical lecithin:cholesterol acyltransferase defi - ciency. Biochemistry . 44 : 14353-14366.
20. Li , X. , K. Kypreos , E. E. Zanni , and V. Zannis . 2003 . Domains of apoE required for binding to apoE receptor 2 and to phospholipids: Implications for the functions of apoE in the brain. Biochemistry . 42 : 10406-10417.
21. Fielding , C. J. , and P. E. Fielding . 1996 . Two-dimensional nondenaturing electrophoresis of lipoproteins: applications to high-density lipoprotein speciation. Methods Enzymol. 263 : 251-259.
22. Lalazar , A. , K. H. Weisgraber , S. C. Rall , Jr ., H. Giladi , T. L. Innerarity , A. Z. Levanon , J. K. Boyles, B. Amit, M. Gorecki, R. W. Mahley, et al . 1988 . Site-specific mutagenesis of human apolipoprotein E. Receptor binding activity of variants with single amino acid substitutions. J. Biol. Chem. 263 : 3542-3545.
23. Chappell , D. A. 1989 . High receptor binding affi nity of lipoproteins in atypical dysbetalipoproteinemia (type III hyperlipoproteinemia). J. Clin. Invest. 84 : 1906-1915.
24. Hui , D. Y. , T. L. Innerarity , and R. W. Mahley . 1984 . Defective hepatic lipoprotein receptor binding of beta-very low density lipoproteins from type III hyperlipoproteinemic patients. Importance of apolipoprotein E. J. Biol. Chem. 259 : 860-869.
25. Weisgraber , K. H. 1990 . Apolipoprotein E distribution among human plasma lipoproteins: role of the cysteine-arginine interchange at residue 112. J. Lipid Res. 31 : 1503-1511.
26. Steinmetz , A. , C. Jakobs , S. Motzny , and H. Kaffarnik . 1989 . Differential distribution of apolipoprotein E isoforms in human plasma lipoproteins. Arteriosclerosis . 9 : 405-411.
27. Ji , Z. S. , S. Fazio , and R. W. Mahley . 1994 . Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia. J. Biol. Chem. 269 : 13421-13428.
28. Havel , R. J. , L. Kotite , J. P. Kane , P. Tun , and T. Bersot . 1983 . Atypical familial dysbetalipoproteinemia associated with apolipoprotein phenotype E3/3. J. Clin. Invest. 72 : 379-387.
29. Rall , S. C. , Jr ., Y. M. Newhouse , H. R. Clarke , K. H. Weisgraber , B. J. McCarthy , R. W. Mahley , and T. P. Bersot. 1989 . Type III hyperlipoproteinemia associated with apolipoprotein E phenotype E3/3. Structure and genetics of an apolipoprotein E3 variant. J. Clin. Invest. 83 : 1095-1101.
30. Fazio , S. , Y. L. Lee , Z. S. Ji , and S. C. Rall , Jr . 1993 . Type III hyperlipoproteinemic phenotype in transgenic mice expressing dysfunctional apolipoprotein E. J. Clin. Invest. 92 : 1497-1503.
31. Fazio , S. , Y. Horie , W. S. Simonet , K. H. Weisgraber , J. M. Taylor , and S. C. Rall , Jr . 1994 . Altered lipoprotein metabolism in transgenic mice expressing low levels of a human receptor-bindingdefective apolipoprotein E variant. J. Lipid Res. 35 : 408-416.
32. Fazio , S. , K. R. Marotti , Y. L. Lee , C. K. Castle , G. W. Melchior , and S. C. Rall , Jr . 1994 . Co-expression of cholesteryl ester transfer protein and defective apolipoprotein E in transgenic mice alters plasma cholesterol distribution. Implications for the pathogenesis of type III hyperlipoproteinemia. J. Biol. Chem. 269 : 32368-32372.
33. Drosatos , K. , D. Sanoudou , K. E. Kypreos , D. Kardassis , and V. I. Zannis . 2007 . A dominant negative form of the transcription factor c-Jun affects genes that have opposing effects on lipid homeostasis in mice. J. Biol. Chem. 282 : 19556-19564.
34. Koukos , G. , A. Chroni , A. Duka , D. Kardassis , and V. I. Zannis . 2007 . LCAT can rescue the abnormal phenotype produced by the Downloaded from www.jlr.org at ELSEVIER BV, on December 29, 2010 natural ApoA-I mutations (Leu141Arg)Pisa and (Leu159Arg)FIN. Biochemistry . 46 : 10713-10721.
35. Miettinen , H. E. , H. Gylling , T. A. Miettinen , J. Viikari , L. Paulin , and K. Kontula . 1997 . Apolipoprotein A-IFin. Dominantly inherited hypoalphalipoproteinemia due to a single base substitution in the apolipoprotein A-I gene. Arterioscler. Thromb. Vasc. Biol. 17 : 83-90.
36. Jong , M. C. , V. E. Dahlmans , M. H. Hofker , and L. M. Havekes . 1997 . Nascent very-low-density lipoprotein triacylglycerol hydrolysis by lipoprotein lipase is inhibited by apolipoprotein E in a dosedependent manner. Biochem. J. 328 : 745-750.
37. Rensen , P. C. , and T. J. van Berkel . 1996 . Apolipoprotein E effectively inhibits lipoprotein lipase-mediated lipolysis of chylomicronlike triglyceride-rich lipid emulsions in vitro and in vivo. J. Biol. Chem. 271 : 14791-14799.
38. Salinelli , S. , J. Y. Lo , M. P. Mims , E. Zsigmond , L. C. Smith , and L. Chan . 1996 . Structure-function relationship of lipoprotein lipasemediated enhancement of very low density lipoprotein binding and catabolism by the low density lipoprotein receptor. Functional importance of a properly folded surface loop covering the catalytic center. J. Biol. Chem. 271 : 21906-21913.
39. Medh , J. D. , S. L. Bowen , G. L. Fry , S. Ruben , M. Andracki , I. Inoue , et al . 1996 . Lipoprotein lipase binds to low density lipoprotein receptors and induces receptor-mediated catabolism of very low density lipoproteins in vitro. J. Biol. Chem. 271 : 17073-17080.
40. Huang , Y. , X. Q. Liu , S. C. Rall , Jr ., and R. W. Mahley . 1998 . Apolipoprotein E2 reduces the low density lipoprotein level in transgenic mice by impairing lipoprotein lipase-mediated lipolysis of triglyceride-rich lipoproteins. J. Biol. Chem. 273 : 17483-17490.
41. Huang , Y. , X. Q. Liu , S. C. Rall , Jr ., J. M. Taylor , A. Von Eckardstein , G. Assmann , and R. W. Mahley. 1998 . Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia. J. Biol. Chem. 273 : 26388-26393.
42. Wetterau , J. R. , L. P. Aggerbeck , S. C. Rall , Jr ., and K. H. Weisgraber . 1988 . Human apolipoprotein E3 in aqueous solution. I. Evidence for two structural domains. J. Biol. Chem. 263 : 6240-6248.
43. Aggerbeck , L. P. , J. R. Wetterau , K. H. Weisgraber , C. S. Wu , and F. T. Lindgren . 1988 . Human apolipoprotein E3 in aqueous solution. II. Properties of the amino- and carboxyl-terminal domains. J. Biol. Chem. 263 : 6249-6258.
44. Wilson , C. , M. R. Wardell , K. H. Weisgraber , R. W. Mahley , and D. A. Agard . 1991 . Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. Science . 252 : 1817-1822.
45. Dong , L. M. , C. Wilson , M. R. Wardell , T. Simmons , R. W. Mahley , K. H. Weisgraber , and D. A. Agard. 1994 . Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. J. Biol. Chem. 269 : 22358-22365.
46. Dong , L. M. , and K. H. Weisgraber . 1996 . Human apolipoprotein E4 domain interaction. Arginine 61 and glutamic acid 255 interact to direct the preference for very low density lipoproteins. J. Biol. Chem. 271 : 19053-19057.
47. Weisgraber , K. H. 1994 . Apolipoprotein E: structure-function relationships. Adv. Protein Chem. 45 : 249-302.
48. Mahley , R. W. , K. H. Weisgraber , and Y. Huang . 2006 . Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc. Natl. Acad. Sci. USA . 103 : 5644-5651.
49. Kypreos , K. E. , and V. I. Zannis . 2006 . LDL receptor deficiency or apoE mutations prevent remnant clearance and induce hypertriglyceridemia in mice. J. Lipid Res. 47 : 521-529.
50. Zannis , V. I. , A. Chroni , K. E. Kypreos , H. Y. Kan , T. B. Cesar , E. E. Zanni , and D. Kardassis. 2004 . Probing the pathways of chylomicron and HDL metabolism using adenovirus-mediated gene transfer. Curr. Opin. Lipidol. 15 : 151-166.
51. Lalazar , A. , and R. W. Mahley . 1989 . Human apolipoprotein E. Receptor binding activity of truncated variants with carboxyl-terminal deletions. J. Biol. Chem. 264 : 8447-8450.